MINNEAPOLIS, June 7 /PRNewswire-FirstCall/ -- Advanced Bio-Surfaces, Inc., (ABS) an orthopedic implant developer and manufacturer announced today that over 200 implants have been completed in the United States using the OrthoGlide Medial Knee implant. The OrthoGlide is a minimally invasive implant designed to relieve chronic, disabling pain, due to moderate osteoarthritis of the medial compartment of the knee.
"There has been a significant increase in the number of orthopedic surgeons interested in attending the surgeon training programs for the OrthoGlide," said Dr. Jeff Felt, Chairman and CEO of Advanced Bio-Surfaces. "The number of trained surgeons has more than doubled in the last six months, proving that orthopedic surgeons want a minimally invasive knee implant option for their patients with painful osteoarthritis of the knee. Approximately 100 implants were performed during the first 11 months of the commercial availability of OrthoGlide. The second group of 100 implants, which brought the implant total in the United States to 200, was performed within four months. ABS is encouraged by the desire of patients and surgeons to seek an alternative that may delay the need for a total knee replacement."
Orthopaedic surgeon, Dave Trotter, M.D., President and Founder of The Center for Sports Orthopaedics in Chicago, Illinois is one of the most experienced implanters of the OrthoGlide. Dr. Trotter said, "The appeal of the OrthoGlide device is both the relative straightforwardness of the procedure and stability of the implant. Surgeons can offer their patients pain relief, through a minimally invasive bone conserving procedure which requires no screws or cement when compared to total knee and unicompartmental replacements. This new technology can offer positive clinical outcomes to patients and provides a less invasive choice in the continuum of care."
About Advanced Bio-Surfaces, Inc.
ABS is a privately held company dedicated to the development of innovative joint restoration products. The company's first product, the OrthoGlide Medial Knee Implant, is intended for treatment of patients with moderate osteoarthritis of the medial compartment. The company received 510(k) clearance to market from the U.S. Food and Drug Administration (FDA) and CE mark notification from its Notified Body, in February 2006. For additional information contact ABS at 952.912.5400 or visit the website at http://www.advbiosurf.com.
Advanced Bio-Surfaces, Inc.
CONTACT: Robert Siegfried, VP, Finance and Administration of AdvancedBio-Surfaces, Inc., +1-952-912-5400